Much reduced cash outflow, despite the deferral of receipts into Q4.
They’ve taken a massive 70% out of their staff costs, yet they’re still budgeting $1m for R&D in Q4 on new sensor design.
Q4 revenues should be much higher (rising Astra Zeneca volumes and payment for delayed production). 2019-20 revenue projections could surprise on the upside as the roll out has a long way to go.
Looks like they’ll end Q4 with $500k to $1m net cash. The company is well embedded with Astra Zeneca, who are also a large shareholder. That gives comfort.
This is a hot sector, so I’m awaiting strategic developments. The valuation gap between Adherium’s AUD 6m market cap and its big rival Propeller’s USD 225m is a joke.
- Forums
- ASX - By Stock
- ADR
- Ann: Appendix 4C - quarterly
Ann: Appendix 4C - quarterly, page-2
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ADR (ASX) to my watchlist
|
|||||
Last
1.4¢ |
Change
-0.002(12.5%) |
Mkt cap ! $10.62M |
Open | High | Low | Value | Volume |
1.5¢ | 1.5¢ | 1.4¢ | $2.688K | 186.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 269000 | 1.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.6¢ | 28527 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 269000 | 0.015 |
5 | 404620 | 0.014 |
3 | 265520 | 0.013 |
3 | 246580 | 0.012 |
2 | 696818 | 0.011 |
Price($) | Vol. | No. |
---|---|---|
0.016 | 28527 | 1 |
0.017 | 432462 | 1 |
0.019 | 99985 | 1 |
0.020 | 120000 | 1 |
0.021 | 391000 | 2 |
Last trade - 10.10am 09/08/2024 (20 minute delay) ? |
Featured News
BOE
Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan
NEU
Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
NEWS
Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo
NEWS
Is oil undervalued?
ADR (ASX) Chart |